Research landscape and emerging trends of diabetes-associated cognitive dysfunction: a bibliometric analysis.
CiteSpace
VOSviewer
bibliometric analysis
cognitive dysfunction
diabetes
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
04
2023
accepted:
14
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Diabetes-associated cognitive dysfunction (DACD) is a common and serious complication in diabetes and has a high impact on the lives of both individuals and society. Although a number of research has focused on DACD in the past two decades, there is no a study to systematically display the knowledge structure and development of the field. Thus, the present study aimed to show the landscape and identify the emerging trends of DACD research for assisting researchers or clinicians in grasping the knowledge domain faster and easier and focusing on the emerging trends in the field. We searched the Web of Science database for all DACD-related studies between 2000 and 2022. Bibliometric analysis was conducted using the VOSviewer, CiteSpace, Histcite, and R bibliometric package, revealing the most prominent research, countries, institutions, authors, journals, co-cited references, and keywords. A total of 4,378 records were selected for analysis. We found that the volume of literature on DACD has increased over the years. In terms of the number of publications, the USA ranked first. The most productive institutions were the University of Washington and the University of Pittsburgh. Furthermore, Biessels GJ was the most productive author. This study systematically illustrated advances in DACD over the last 23 years. Current findings suggest that exploring potential mechanisms of DACD and the effect of anti-diabetes drugs on DACD are the hotspots in this field. Future research will also focus on the development of targeted drugs that act on the DACD signaling pathway.
Sections du résumé
Background
UNASSIGNED
Diabetes-associated cognitive dysfunction (DACD) is a common and serious complication in diabetes and has a high impact on the lives of both individuals and society. Although a number of research has focused on DACD in the past two decades, there is no a study to systematically display the knowledge structure and development of the field. Thus, the present study aimed to show the landscape and identify the emerging trends of DACD research for assisting researchers or clinicians in grasping the knowledge domain faster and easier and focusing on the emerging trends in the field.
Methods
UNASSIGNED
We searched the Web of Science database for all DACD-related studies between 2000 and 2022. Bibliometric analysis was conducted using the VOSviewer, CiteSpace, Histcite, and R bibliometric package, revealing the most prominent research, countries, institutions, authors, journals, co-cited references, and keywords.
Results
UNASSIGNED
A total of 4,378 records were selected for analysis. We found that the volume of literature on DACD has increased over the years. In terms of the number of publications, the USA ranked first. The most productive institutions were the University of Washington and the University of Pittsburgh. Furthermore, Biessels GJ was the most productive author.
Conclusion
UNASSIGNED
This study systematically illustrated advances in DACD over the last 23 years. Current findings suggest that exploring potential mechanisms of DACD and the effect of anti-diabetes drugs on DACD are the hotspots in this field. Future research will also focus on the development of targeted drugs that act on the DACD signaling pathway.
Identifiants
pubmed: 37575299
doi: 10.3389/fnins.2023.1214301
pmc: PMC10416239
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1214301Informations de copyright
Copyright © 2023 He, Liang, Zhu, Wang, Lin, Wu, Zhang, Lin and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Références
Front Aging Neurosci. 2018 Jul 27;10:227
pubmed: 30100873
Nat Rev Endocrinol. 2018 Oct;14(10):591-604
pubmed: 30022099
Diabetologia. 2000 Apr;43(4):500-6
pubmed: 10819245
Nat Neurosci. 2008 Mar;11(3):309-17
pubmed: 18278039
Endocr Rev. 2008 Jun;29(4):494-511
pubmed: 18436709
Nat Rev Neurosci. 2015 Nov;16(11):660-71
pubmed: 26462756
Front Pharmacol. 2021 Dec 03;12:772386
pubmed: 34925030
J Alzheimers Dis. 2019;69(1):135-144
pubmed: 30958355
Lancet Neurol. 2020 Aug;19(8):699-710
pubmed: 32445622
Front Endocrinol (Lausanne). 2022 Jun 01;13:891039
pubmed: 35721719
J Clin Med. 2018 Dec 28;8(1):
pubmed: 30597861
J Neural Transm (Vienna). 2017 Nov;124(11):1431-1454
pubmed: 28766040
Diabetes. 2014 Jul;63(7):2244-52
pubmed: 24931032
Alzheimer Dis Assoc Disord. 2017 Apr-Jun;31(2):107-113
pubmed: 28538088
Diabetes Metab Syndr. 2022 Apr;16(4):102450
pubmed: 35344849
Front Public Health. 2022 Jul 07;10:902825
pubmed: 35875005
J Alzheimers Dis. 2015;47(1):85-94
pubmed: 26402757
Sci Rep. 2017 Sep 26;7(1):12311
pubmed: 28951620
J Endocrinol. 2013 May 28;218(1):1-11
pubmed: 23591914
Front Neurosci. 2022 Nov 17;16:1048565
pubmed: 36466165
Eur J Pharmacol. 2008 Jul 28;589(1-3):176-9
pubmed: 18602098
Lancet Neurol. 2006 Jan;5(1):64-74
pubmed: 16361024
Scientometrics. 2010 Aug;84(2):523-538
pubmed: 20585380
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Drugs Today (Barc). 2006 Nov;42(11):741-54
pubmed: 17171193
Front Pharmacol. 2020 Jun 05;11:842
pubmed: 32581801
J Alzheimers Dis. 2015;44(3):897-906
pubmed: 25374101
Eur J Neurosci. 2013 Mar;37(5):839-49
pubmed: 23240760
Diabetes. 2015 Nov;64(11):3927-36
pubmed: 26216852
Curr Probl Cardiol. 2022 Oct;47(10):101311
pubmed: 35810847
Neurotoxicology. 2019 May;72:74-84
pubmed: 30742852
Health Aff (Millwood). 2023 Jan;42(1):6-17
pubmed: 36516360
Proc Natl Acad Sci U S A. 2004 Apr 6;101 Suppl 1:5303-10
pubmed: 14724295
Arch Intern Med. 2000 Jan 24;160(2):174-80
pubmed: 10647755
Semin Ophthalmol. 2021 May 19;36(4):139
pubmed: 33952018
Biomed Pharmacother. 2023 Feb;158:114206
pubmed: 36916433
Front Cell Neurosci. 2020 Jun 24;14:170
pubmed: 32670025
Diabetes Care. 2016 Feb;39(2):300-7
pubmed: 26681727
Front Immunol. 2022 Jun 10;13:910400
pubmed: 35757713
Front Pharmacol. 2021 May 24;12:667874
pubmed: 34108878
Diabetes. 2006 Apr;55(4):1106-13
pubmed: 16567535
Lancet Neurol. 2015 Mar;14(3):329-40
pubmed: 25728442
Diabetes Care. 2020 Nov;43(11):2691-2701
pubmed: 32967921
Int J Ophthalmol. 2021 Jun 18;14(6):903-914
pubmed: 34150547
Global Health. 2021 Jan 4;17(1):1
pubmed: 33397377
Diabetologia. 2020 Jan;63(1):3-9
pubmed: 31420699
Nat Rev Neurol. 2018 Mar;14(3):168-181
pubmed: 29377010
Front Mol Biosci. 2022 Jul 18;9:851966
pubmed: 35923469
Front Cardiovasc Med. 2022 May 04;9:899235
pubmed: 35600466
Diabetes Care. 2005 Mar;28(3):726-35
pubmed: 15735218
Lancet. 2012 Jun 16;379(9833):2291-9
pubmed: 22683129
Eur Neuropsychopharmacol. 2014 Dec;24(12):1967-81
pubmed: 24726582
Lancet Diabetes Endocrinol. 2015 Jan;3(1):75-89
pubmed: 25163604